The proteins are expressed in a the scalable non-mammalian ExpressTec system. No animal- or human-derived inputs enter the process from gene to final product.
Recombinant, animal-origin-free biomanufacturing
InVitria takes animal-derived components out of biomanufacturing.
We manufacture recombinant, animal-origin-free proteins and chemically defined media for cell culture, biomanufacturing, and final formulation, from gene to final product.
- 19
- Years removing animal-derived components
- >1,000
- Active customers worldwide
- >40
- Products on the market using InVitria’s components
- 7
- Approved therapeutics using InVitria proteins
- >40
- Countries served
Our Mission
AOF, from start to finish.
InVitria exists to remove animal-derived components from the materials used to make medicines. The recombinant proteins and chemically defined media we manufacture are designed to carry a process from gene to final product without a single input collected from blood, serum, or tissue. That is the entire purpose of the company, not one capability.
Validation and partnership
The standards other serious organizations already apply.
Regulatory precedent

InVitria’s recombinant human serum albumin is an excipient in ERVEBO, the first FDA- and EMA-approved vaccine to include recombinant human serum albumin in final formulation.
Approved in ERVEBO by the U.S. FDA and the European Medicines Agency (EMA).
Distribution partner

Evonik, a specialty chemicals manufacturer reporting €14.1 billion in FY2025 revenue, partnered with InVitria to expand access to animal-free albumin.
Co-development partner

InVitria and Cellevate AB are collaborating to pair Cellevate’s Cellevat3d nanofiber microcarrier with InVitria recombinant proteins for animal-origin-free viral vaccine manufacturing.
Manufacturing and quality
Built to a documented quality system.
- Certified facility
- Junction City, Kansas, ISO 9001:2015 certified and cGMP compliant, made in the USA.
- Documented quality system
- A quality management system a QA reviewer can audit.
- Lot-specific Certificate of Analysis
- Released with every batch, with the specifics that go into a filing.
Questions, answered
The questions buyers ask first.
A starting point for evaluation. The full list goes deeper on quality and regulatory.
Manufacturing runs in an ISO 9001:2015 certified, cGMP compliant facility in Junction City, Kansas. A lot-specific Certificate of Analysis is released with every batch.
InVitria’s recombinant proteins are used in clinical and on-market manufacturing and final formulation. InVitria’s recombinant human serum albumin is an approved excipient in multiple therapeutics, including ERVEBO, the first FDA- and EMA-approved vaccine to include recombinant human serum albumin as an injectable excipient.
You can order direct from InVitria, with North American and European fulfillment, the latter through Rotterdam. Products are also available through Fisher Scientific, VWR, and the Labviva procurement platform among other regional distributors around the world.
The materials support medical devices, cell therapy, gene therapy, vaccines, biologics, and as a final formulation excipient.
ExpressTec is InVitria’s recombinant expression platform and development services entity. It has been in continuous commercial production for more than 25 years.
Talk to the team
Talk through your application with our team.
The next step is a conversation about your specific cell line, modality, and stage.